vs
Side-by-side financial comparison of GCI Liberty, Inc. (GLIBA) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
GCI Liberty, Inc. is the larger business by last-quarter revenue ($257.0M vs $158.6M, roughly 1.6× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -150.6%, a 221.8% gap on every dollar of revenue. Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $21.0M).
GCI Communication Corp (GCI) is a telecommunications corporation operating in Alaska. Through its own facilities and agreements with other providers, GCI provides Internet access, landline, and cellular telephone service. It is a subsidiary of GCI Liberty, Inc.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
GLIBA vs STOK — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $257.0M | $158.6M |
| Net Profit | $-387.0M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | -189.9% | 70.2% |
| Net Margin | -150.6% | 71.2% |
| Revenue YoY | — | 3661.1% |
| Net Profit YoY | — | 528.0% |
| EPS (diluted) | $-13.34 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $257.0M | — | ||
| Q2 25 | $261.0M | — | ||
| Q1 25 | — | $158.6M | ||
| Q4 24 | — | $22.6M | ||
| Q2 23 | — | $-2.5M |
| Q3 25 | $-387.0M | — | ||
| Q2 25 | $27.0M | — | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q2 23 | — | $-30.7M |
| Q3 25 | -189.9% | — | ||
| Q2 25 | 19.5% | — | ||
| Q1 25 | — | 70.2% | ||
| Q4 24 | — | -60.4% | ||
| Q2 23 | — | 1340.7% |
| Q3 25 | -150.6% | — | ||
| Q2 25 | 10.3% | — | ||
| Q1 25 | — | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q2 23 | — | 1235.6% |
| Q3 25 | $-13.34 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $1.90 | ||
| Q4 24 | — | $-0.15 | ||
| Q2 23 | — | $-0.69 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $124.0M | $274.8M |
| Total DebtLower is stronger | $985.0M | — |
| Stockholders' EquityBook value | $1.4B | $350.1M |
| Total Assets | $3.0B | $406.9M |
| Debt / EquityLower = less leverage | 0.72× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $124.0M | — | ||
| Q2 25 | $104.0M | — | ||
| Q1 25 | — | $274.8M | ||
| Q4 24 | — | $128.0M | ||
| Q2 23 | — | $192.1M |
| Q3 25 | $985.0M | — | ||
| Q2 25 | $987.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $350.1M | ||
| Q4 24 | — | $229.0M | ||
| Q2 23 | — | $190.2M |
| Q3 25 | $3.0B | — | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | — | $406.9M | ||
| Q4 24 | — | $271.6M | ||
| Q2 23 | — | $256.9M |
| Q3 25 | 0.72× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $76.0M | $131.8M |
| Free Cash FlowOCF − Capex | $21.0M | $131.7M |
| FCF MarginFCF / Revenue | 8.2% | 83.0% |
| Capex IntensityCapex / Revenue | 21.4% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $76.0M | — | ||
| Q2 25 | $226.0M | — | ||
| Q1 25 | — | $131.8M | ||
| Q4 24 | — | $-23.2M | ||
| Q2 23 | — | $-21.8M |
| Q3 25 | $21.0M | — | ||
| Q2 25 | $107.0M | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q2 23 | — | $-22.6M |
| Q3 25 | 8.2% | — | ||
| Q2 25 | 41.0% | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q2 23 | — | 912.5% |
| Q3 25 | 21.4% | — | ||
| Q2 25 | 45.6% | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q2 23 | — | -33.8% |
| Q3 25 | — | — | ||
| Q2 25 | 8.37× | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
